Brain Tumor Clinical Trials

Study: 2021-0041, A Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (anti-PD-L1) in Combination with Cabozantinib in Patients with Recurrent Glioblastoma (rGBM)

Physician name: Dr. Shiao-Pei Weathers
Phase I/II
Treatment agent: Cabozantinib, Atezolizumab
Disease: Glioblastoma
To learn more, visit ClinicalTrials.gov - NIH link: NCT05039281

Study: 2019-1035, Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients with Newly Diagnosed MGMT Unmethlated Glioblastoma or Gliosarcoma

Physician name: Dr. Shiao-Pei Weathers
Phase I
Treatment agent: Nedisertib, Temozolomide
Disease: Glioblastoma, Gliosarcoma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04555577

Study: 2019-0216, A Trial  to Evaluate Multiple Regimens in Newly Diagnosed and recurrent Glioblastoma (GBM AGILE)
Physician name: Dr. Shiao-Pei Weathers
Phase II/III
Treatment agent: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Disease: Glioblastoma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03970447

Study: NRG-BN001, Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Physician name: Dr. Andrew Bishop 
Phase II
Treatment agent: Radiation, Temozolomide
Disease: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT02179086

Study: 2015-0953, Oncolytic Adenovirus DNX-2401 in Treating Patients with Recurrent High-Grade Glioma
Physician name: Dr. Frederick Lang
Phase I
Treatment agent: Oncolytic Adenovirus Ad5-DNX-2401
Disease: IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03896568

Study: 2016-0859, A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype

Physician name: Dr. Carlos Kamiya Matsuoka
Treatment agent: Pembrolizumab
Disease: Glioma, Recurrent Malignant Glioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT02658279

Study: 2019-0216, A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)
Physician name: Dr. Shiao-Pei Weathers
Phase II/III
Treatment agent: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Disease: Glioblastoma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03970447

Study: 2020-0758, A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme 
Physician name: Dr. Shiao-Pei Weathers
Phase I/II
Treatment agent: ACT001, ACT001 + Pembrolizumab
Disease: Recurrent Glioblastoma Multiforme
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT05053880

Study: 2021-0625, A Phase 1b Escalation/Dose Expansion Study of Icapamespib (PU-AD) in Patients with Recurrent Malignant Glioma 
Physician name: Dr. Vinay Puduvalli
Phase I
Treatment agent: Icapamespib
Disease: Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma, Grade 3 or 4 Astrocytoma, Glioblastoma Surgery
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04782609

Study: 2018-0045, A Phase II, Open-Label Study of ONC201 in Adults with Recurrent High-Grade Glioma
Physician name: Dr. Carlos Kamiya Matsuoka 
Phase II
Treatment agent: ONC201
Disease: Glioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03295396  

Study: 2020-0124, Seizure control as a new metric in assessing efficacy of tumor treatment in patients with low grade glioma
Physician name: Dr. Ashley Aaroe
Treatment agent: Survey Administration
Disease: Brain Neoplasm, Low Grade Glioma, Seizure Disorder
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04553757

Study: 2012-0441, Prospective Assessment of Correlative and Tissue Biomarkers in Glioma Patients (The PROACTIVE-Glioma Program) - A Biomarker-Driven Program for Clinical Trial Development for Newly Diagnosed and Recurrent Glioma patients
Physician name: Dr. Vinay Puduvalli
Disease: Newly Diagnosed and Recurrent Glioma

Study: 2018-0564, Feasibility of Monitoring Step Count as a Measure of  Physical Activity in Patients with Newly Diagnosed Glioma Patients Undergoing Radiation Therapy
Physician name: Dr. Shiao-Pei Weathers
Disease: Glioma, Radiation Therapy Patient
To learn more, visit ClinicalTrials.gov -NIH link: NCT No: NCT04186832

Study: NRG-BN005, A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas. 
Physician name: Dr. David Grosshans
Disease: 1p/19q Co-deletion, Anaplastic Astrocytoma, Diffuse Astrocytoma, Glioma, IDH1 Gene Mutation, IDH2 Gene Mutation, Oligoastrocytoma, Oligodendroglioma, WHO Grade III Glioma
Treatment Agent: Temozolomide
To learn more, visit ClinicalTrials.gov -NIH link: NCT No: NCT03180502

Study: 2019-1223, Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Physician name: Dr. Jeffrey Weinberg
Disease: Glioma
Treatment Agent: Rhenium Liposome Treatment
To learn more, visit ClinicalTrials.gov -NIH link: NCT No: NCT01906385

Study: 2019-0715, Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas 
Physician name: Dr. Debra Yeboa
Phase II
Disease: Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, IDH-Wildtype, Glioblastoma, Oligoastrocytoma, Oligodendroglioma, WHO Grade II Glioma, WHO Grade III Glioma
Treatment Agent: Temozolomide
To learn more, visit ClinicalTrials.gov -NIH link: NCT No: NCT04623931

Study: #ALLIANCEA07160, Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma
Physician name: Dr. Carlos Kamiya Matsuoka
Phase II
Treatment agent: Vemurafenib, Cobimetinib
Disease: BRAF V600E Mutation Present, Papillary Craniopharyngioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03224767

Study: 2020-1111, Post-Surgical Stereotactic Radiosurgery (SRT) Versus GammaTile
Physician name: Dr. Jeffrey Weinberg
Phase III
Treatment agent: Stereotactic Radiation Therapy
Disease: Newly Diagnosed Metastatic Brain Tumors
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04365374

Study: 2019-1064, Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Physician name: Dr. Barbara O'Brien
Phase II
Treatment agent: Abemaciclib, PI3K Inhibitor GDC-0084, Entrectinib
Disease: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03994796

Study: PA16-0496, Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN)
Physician name: Dr. Sujit Prabhu
Treatment agent: NeuroBlate System
Disease: Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT02392078

Study: 2020-0399, Early Supportive Care and Rehabilitation Intervention for Patients with High Grade Astrocytoma
Physician name: Dr. Shiao-Pei Weathers

Study: 2020-0904, Immune Checkpoint Inhibitor Nivolumab in People with Recurrent Select Rare CNS Cancers
Physician name: Dr. Carlos Kamiya Matsuoka
Phase II
Treatment agent: Nivolumab
Disease: Medulloblastoma, Ependymoma, Pineal RegionTumors, Choroid Plexus Tumors, Atypical/Malignant Meningioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03173950

Study: NCT04315064, Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma
Physician name: Dr. David Sandberg
Phase I
Treatment agent: MTX110
Disease: Medulloblastoma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04315064

Study: 2016-0684, A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas 
Physician name: Dr. Susan McGovern
Disease: Meningioma, Brain Tumor
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT02693990

Study: 2020-0642, Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
Physician name: Dr. Shaan Raza
Phase III
Disease: Meningioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04305470

Study: PA18-0742, Metastatic Tumor Research and Outcomes Network (MTRON)
Physician name: Dr. Laurence Rhines
Disease: Metastatic Spine Tumor
To learn more, visit ClinicalTrials.gov - NIH link: No: NCT02830451

Study: 2020-0493, Patient Perceptions Around Quality of Care through Telemedicine in Neuro-Oncology 
Physician name: Dr. Barbara O'Brien                                                                 
Disease: Central Nervous System Neoplasm, Leptomeningeal Neoplasm, Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04988009

Study: 2015-0775,  Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brian Tumors
Physician name: Dr. Sujit Prabhu
Disease: Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Brain Neoplasm
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT02754544

Study: 2017-0663, Safety of MRI Compatible Hardware for MRI-based Image Guidance During Spine Surgery
Physician name: Dr. Claudio Tatsui
Phase I
Treatment agent: N/A
Disease: Thoracic Spine Neoplasm
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04563806